The effect of amlodipine on endothelial function in young adults with a strong family history of premature coronary artery disease: A randomised double blind study

Atherosclerosis

Volumn 154, Issue 1, 2001, Pages 171-177

  Clarkson, Peter ^a   Mullen, Michael J ^a   Donald, Ann E ^a   Powe, Amanda J ^a   Thomson, Hyeyoung ^a   Thorne, Sara A ^a   Bull, Teresa ^a   Deanfield, John E ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Amlodipine; Endothelium; Family history; Ultrasound

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; GLYCERYL TRINITRATE; PLACEBO;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD FLOW; BRACHIAL ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FAMILY HISTORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AMLODIPINE; BRACHIAL ARTERY; CALCIUM CHANNEL BLOCKERS; CORONARY DISEASE; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; NITROGLYCERIN; REGIONAL BLOOD FLOW; VASODILATOR AGENTS;

EID: 0035192764     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00455-X     Document Type: Article

References (39)

1. Family history as an independent risk factor for coronary artery disease
2. Family history as an independent risk factor for incident coronary artery disease in a high-risk cohort in Utah
3. Parental history is an independent risk factor for coronary artery disease: The Framingham Study
4. Family history as an independent risk factor of coronary artery disease
5. Determinants of severity of coronary artery disease in Australian men and women
6. The increased risk of death from ischaemic heart disease in the first degree relatives of 121 men and 96 women with ischaemic heart disease
7. Searching for the Holy Grail: The cause of diabetes
8. Genetic basis of lipoprotein disorders
9. Can lowering homocysteine levels reduce cardiovascular risk?
10. Genetic variation at the β-fibrinogen locus in relation to plasma fibrinogen concentration and risk of myocardial infarction: The ECTIM study
11. The pathogenesis of atherosclerosis: A perspective for the 1990s
12. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
13. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis
14. Is NO an endogenous antiatherogenic molecule?
15. Cigarette smoking is associated with a dose dependent and potentially reversible impairment of endothelium-dependent dilatation in healthy young adults
16. Endothelial dysfunction in insulin-dependent diabetes mellitus is related to disease duration and LDL-cholesterol levels
17. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level
18. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease
19. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication
20. Randomised trial of cholesterol lowering in 4444 patients with coronary artery disease: The Scandinavian Simvastatin Survival Study (4S)
21. Endothelium-dependent dilatation is impaired in young adults with a family history of premature coronary disease
22. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerosis Therapy (INTACT)
23. A controlled clinical trial to assesss the effect of a calcium channel blocker on the progression of coronary atherosclerosis
24. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels
25. Rationale, design, and baseline characteristics of the Prospective Randomised Evaluation of the Vascular Effects of Norvasc trial (PREVENT)
26. Experimental models to study the prevention of atherosclerosis by calcium antagonists: An overview
27. Calcium antagonists and atherosclerosis. Experimental evidence
28. Actions of the charged dihydropyridine amlodipine in a cell culture model of dietary atherosclerosis
29. Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine and unchanged drugs of this class in cardiac membranes
30. Limits of lipid-lowering therapy: The benefits of amlodipine as an anti-atherosclerotic agent
31. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
32. Estimation of the concentration of low density lipoprotein cholesterol in the plasma without the use of the preparative ultracentrifuge
33. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo
34. Close relation of endothelial function in the human coronary and peripheral circulations
35. Non-invasive measurement of endothelium dependent arterial responses in man: Accuracy and reproducibility
36. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events trial Investigators
37. Antiatherogenic properties of calcium antagonists. State of the art
38. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and Amlodipine